Previous Close | 14.70 |
Open | 14.71 |
Bid | 14.70 x 3000 |
Ask | 14.79 x 4000 |
Day's Range | 14.70 - 14.70 |
52 Week Range | 14.70 - 14.70 |
Volume | |
Avg. Volume | N/A |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 18.67 |
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland and Boston MA, April 12, 2023 – Chiesi Farmaceutici S.p.A. (“Chiesi”), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc (“Amryt”) (Nasdaq: AMYT),
Turnover at €2 billion 749 million, with growth of 13.6% over 2021The European market remains at the center, with significant international developmentThe distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare diseases) 12% and Care (special care & consumer healthcare) 15%In 2022, Chiesi invested 21.4% of its turnover in Research & DevelopmentThe total number of employees rises to more than 6,500 people, 55% women and 45% menThe Grou
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3, 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that the High Court of Justice of England and Wales (the “Court”) has sanctioned the scheme of arra